Physician profile
Derek Ramsey
NPI 1992218911
$7,866.10
in general payments reported to CMS, 2019-2025
28 companies · $949 in 2025
The $949 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,403 · 2022: $1,777 · 2023: $1,787 · 2024: $1,950 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,306 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,306.33 |
| Education | $379.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,231.32 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,208.99 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $996.81 | 2021-2025 | |
| Janssen Biotech, INC. | $566.85 | 2021-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $561.98 | 2021-2024 | Dupixent, Libtayo |
| Amgen INC. | $458.82 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $411.69 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $352.89 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $298.16 | 2024-2025 | Zoryve |
| Ucb, INC. | $272.40 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $243.17 | 2022-2024 | Sotyktu |
| Pfizer INC. | $198.53 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $157.15 | 2021-2025 | |
| Dermavant Sciences, INC. | $129.76 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $112.87 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $111.38 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.92 | 2022-2024 | Spevigo |
| Incyte Corporation | $82.57 | 2021-2023 | Opzelura |
| Genentech USA, INC. | $68.88 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $66.28 | 2021 | |
| Almirall LLC | $51.38 | 2023-2024 | Seysara |
| Galderma Laboratories, L.P. | $46.35 | 2022-2025 | Nemluvio |
| Leo Pharma INC. | $45.66 | 2021-2025 | Anzupgo, Adbry |
| Epi Health, LLC | $28.97 | 2021-2022 | |
| Kyowa Kirin, INC. | $23.50 | 2022 | |
| Smith+Nephew, INC. | $18.65 | 2022 | |
| Botanix Sb INC | $15.32 | 2025 | Sofdra |
| Organon LLC | $6.85 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.